Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Study Identifier
191622-520
CT.gov Identifier
NCT00910520
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Bladder Disorder - Overactive Bladder
    • Study Drug
  • onabotulinumtoxinA
  • normal saline
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Symptoms of OAB (frequency/urgency) with urinary incontinence for at least 6 months * Inadequate response or limiting side effects with anticholinergics for the treatment of OAB
    Exclusion Criteria:
    * Overactive Bladder caused by neurological condition * Patient has predominance of stress incontinence * History or evidence of pelvic or urological abnormality

    Protocol Summary

    The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.

    Study Locations

    Location
    Status
    Location
    Laguna Hills, California, United States
    Status
    Not applicable
    Location
    Ghent, Belgium
    Status
    Not applicable
    Location
    Prague, Czech Republic
    Status
    Not applicable
    Location
    Tübingen, Germany
    Status
    Not applicable
    Location
    Warsaw, Poland
    Status
    Not applicable
    Location
    Moscow, Russian Federation
    Status
    Not applicable
    Showing {first} - {last} of {total} Results